MANY HAVE BEEN SAVED
Speaking of gene therapy, I wrote about it recently, if you remember. It’s possible that it will soon become mainstream. A few months ago, Kite Pharma introduced a method for treating cancer that strengthens the immune cells, which leads to a regression of the disease in patients at the terminal stage. The results are cautiously preliminary.
But even these preliminary results (not in mice!) are impressive: the therapy caused a complete submission of the disease in 36 out of 101 patients with non-Hodgkin’s lymphoma, and 41 had a significant reduction in symptoms. Before treatment, all of these people were practically doomed, as all were in the terminal stage of disease.
“The data is simply incredible,” said an expert in blood cancers, one of the authors of the study. “These were serious patients without other treatment options.” The essence of CAR-T therapy consists of filtering the patient’s blood, extracting immune cells, and arming them with new proteins that can recognize cancer.
While neither side effects nor long-term benefits are known, we have seen the light!
Non-Hodgkin’s lymphoma is one of three types of blood cancer. The majority of people at this stage live 6 months, but in this group the majority lived for 9 months, and a third of them had the chance to heal completely. It must be known that not all of the participants in the case were so good – two died of complications, but the numbers speak for themselves.
Many lives were saved!